Market sentiment analysis. Positive factors. * Launch of a creative melanoma awareness campaign * Focus on early detection and health awareness * Engagement with the oncology community at CAMO * Use of relatable visuals to convey important health messages BiopharmaWatch analysis. From its catalyst data and publicly available data · not financial advice Best trade, last catalyst 120-day peak, hindsight Typical move average across 15 past catalysts Lead asset Mezigdomide NDA/BLA · Relapsed or Refractory Multiple Myeloma CALGARY, AB, Nov. 4, 2026 /PRNewswire/ - Bristol Myers Squibb (BMS) Canada, in partnership with TANK Worldwide and Ogilvy Health, today launched "What Summer Leaves Behind," a new disease-awareness campaign that transforms the familiar signs of autumn leaves into a visual reminder of the ABCDE warning signs of melanoma and other skin cancers. The campaign debuts in Calgary during the Canadian Association of Medical Oncologists (CAMO) Annual Scientific Meeting, November 5-7. As summer gives way to fall and Canadians trade shorts and T-shirts for layers, "What Summer Leaves Behind" offers a timely reminder that sun safety shouldn't end with summer and that changes in the skin are worth noticing. On a leaf, asymmetry, jagged borders and changing colors are hallmarks of the season. On skin, similar changes can be a reason to look closer. The campaign uses autumn leaves to bring the ABCDE warning signs of melanoma to life: - A - Asymmetry: Uneven on a leaf. A reason to look closer on your skin. - B - Border: Jagged on a leaf. A reason to look closer on your skin. - C - Colour: Varied on a leaf. A reason to look closer on your skin. - D - Diameter: Oversized on a leaf. A reason to look closer on your skin. - E - Evolution: Ever-changing on a leaf. A reason to look closer on your skin. "BMS is committed to scientific innovation and awareness across major disease areas including melanoma. Early awareness and detection is key to timely diagnosis and intervention. This campaign uses a familiar sign of the changing season to remind Canadians that attention to changes in your health matters year-round," said François Villeneuve, Head of Commercialization, Bristol Myers Squibb Canada. "By launching this initiative as Canada's oncology community gathers at CAMO, our goal is to continue to demonstrate our leadership in melanoma, foster a broader conversation about melanoma awareness and highlight the importance of recognizing potential warning signs associated with a diagnosis." "In health communication, the biggest barrier is often getting people to notice what is hiding in plain sight," said Marty Martinez, Chief Creative Officer at TANK Worldwide and Ogilvy Health. "We saw an unexpected visual connection between the irregularity of autumn leaves and the ABCDE warning signs people are taught to look for on their skin. By bringing those two things together, we're turning something Canadians see every fall into a simple reminder to pay attention to changes in their skin." The bilingual campaign launches this week across Calgary, timed to the CAMO 2026 Annual Scientific Meeting. Creative will appear throughout Calgary International Airport, across downtown digital and skywalk screens, and through geotargeted mobile placements surrounding the meeting venue. Canadians are encouraged to inspect existing moles, take note of any new or changing spots, and talk to their doctor or dermatologist immediately if they notice irregularities. About Bristol Myers Squibb Canada: Transforming Patients' Lives Through Science Bristol Myers Squibb Canada Co. is an indirect wholly-owned subsidiary of Bristol Myers Squibb Company, a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. BiopharmaWatch is pursuing bold science to define what's possible for the future of medicine and the patients BiopharmaWatch serve. For more information, visit BiopharmaWatch at https://www.bms.com/ca/en. About TANK Worldwide TANK Worldwide, part of The Ogilvy Group, is a full-service global advertising agency built on the belief that great ideas need "good company" to thrive. Headquartered in Montreal, Canada, with additional offices in New York, Toronto, and London, the agency is comprised of a curious, brilliant, and unpretentious team dedicated to bringing creative concepts to their full potential. By turning constraints into opportunities, TANK Worldwide creates work that shapes markets and changes lives. For more information, visit https://tankww.com/. About Ogilvy Health Ogilvy Health is focused on driving superior outcomes in the ever-changing healthcare environment, an increasingly complex and evolving marketplace. BiopharmaWatch inspire brands and people to impact the world by keeping its audiences' health and wellness needs at the center of every touchpoint. Ogilvy Health delivers insight, creativity, innovation, and engagement solutions for all healthcare stakeholders, patients, and consumers across the healthcare continuum. Through borderless creativity - operating, innovating, and creating at the intersection of Ogilvy's capabilities and global talent - Ogilvy Health brings forth world-class creative solutions for its clients. For more information, visit OgilvyHealth.com, or follow Ogilvy Health on X, LinkedIn, Facebook, Instagram, and Threads. Frequently asked questions. What is the purpose of the campaign? The campaign aims to raise awareness about melanoma and skin cancer. What does the ABCDE stand for? ABCDE refers to Asymmetry, Border, Colour, Diameter, and Evolution. Where is the campaign launched? The campaign launched in Calgary during the CAMO Annual Scientific Meeting. Who are the partners in this campaign? Bristol Myers Squibb partnered with TANK Worldwide and Ogilvy Health.

Bristol Myers Squibb (BMY) warned that its biggest drug, Eliquis, will face pressure from the fourth quarter of 2026. A loss of exclusivity in Europe is the cause, and continued US growth will only partly offset it. On its October 29 call, management said Eliquis revenue will step down by $1.5 billion to $2 billion in 2027. That is roughly 3% to 4% of the $50.0 billion in revenue the company booked over the last twelve months. Eliquis is still growing fast. Third-quarter 2026 revenue rose 26% to $4.7 billion, and the drug brought in $14.4 billion in fiscal 2025, about 30% of company revenue. Growth medicines rose 12% to $7.7 billion in the quarter. The shares returned 42.9% over the past year and trade at 13.9 times earnings, against 22.8 for the S&P 500.

Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has completed the previously announced planned acquisition of Flexus Biosciences, Inc. The transaction includes full rights to F001287, Flexus’ lead preclinical, small-molecule IDO1-inhibitor targeted for IND filing in the second half of 2015 and an IDO/TDO discovery program that includes its IDO-selective, IDO/TDO dual and TDO-selective compound libraries. A newly formed entity established by the current shareholders of Flexus will retain, from and after the closing, all non-IDO/TDO assets of Flexus including those related to Flexus’ Phase 1 FLT3 and CDK4/6 inhibitor, its earlier stage small-molecule Treg cancer immunotherapy programs, and its current personnel and facilities. About Bristol-Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit